SCHEMBL120858

SCHEMBL120858

Cc1ccc(C(OCc2ccccc2)OCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
TSHR P16473 1/20 0.41
AOC3 Q16853 1/20 0.41
POLB P06746 2/20 0.41
AGXT P21549 2/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11100946 0.86 SLC6A2 (0.50) TSHRAOC3AGXTSLC6A2SLC6A4
SCHEMBL10126406 0.82 CYP1A2 (0.52) TSHRSLC6A2SLC6A4SLC6A3CYP2C19
SCHEMBL11106772 0.81 AOC3 (0.60) CNR2TSHRAOC3POLBAGXT
SCHEMBL120857 0.81 TSHR (0.41) TSHRAOC3AGXTSLC6A2SLC6A4
SCHEMBL11100448 0.81 SLC6A2 (0.56) CNR2TSHRPOLBAGXTSLC6A2
SCHEMBL412975 0.80 CNR1 (0.40) CNR1CNR2TSHRAOC3POLB
SCHEMBL13627603 0.79 TSHR (0.52) TSHRAOC3AGXTSLC6A2SLC6A4
SCHEMBL11957471 0.79 AOC3 (0.38) TSHRAOC3SLC6A2SLC6A4SLC6A3
SCHEMBL19543237 0.79 CNR2 (0.51) CNR2AOC3SLC6A2SLC6A3CYP2C19
SCHEMBL4413012 0.78 SLC6A2 (0.45) TSHRAOC3AGXTSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2359862-B1 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents INTEZYNE TECHNOLOGIES INC (US) 2013-07-24 EP claimed
US-8258190-B2 Encapsulated contrast agents INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-04 US claimed
EP-2359862-A1 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents Intezyne Technologies Inc. (US) 2011-08-24 EP claimed
EP-2073850-B1 HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS INTEZYNE TECHNOLOGIES INC (US) 2010-10-27 EP claimed
EP-2152320-A2 ENCAPSULATED CONTRAST AGENTS Intezyne Technologies Incorporated (US) 2010-02-17 EP claimed
EP-1907444-B1 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES INC (US) 2009-08-19 EP claimed
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-04-09 US claimed
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US claimed
WO-2008134734-A2 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 WO claimed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 US claimed
WO-2008106657-A2 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-09-04 WO claimed
EP-1907444-A2 POLYMERIC MICELLES FOR DRUG DELIVERY Intezyne Technologies Incorporated (US) 2008-04-09 EP claimed
US-20060240092-A1 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell INTEZYNE TECHNOLOGIES, INC. 2006-10-26 US claimed
WO-2006107903-A2 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-10-12 WO claimed
EP-3000833-B1 MICELLES COMPRISING A TRIBLOCK COPOLYMER AND A THERAPEUTIC AGENT INTEZYNE TECH INC (US) 2019-09-04 EP disclosed
US-9944752-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2018-04-17 US disclosed
US-9944754-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2018-04-17 US disclosed
WO-2006074202-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-07-13 WO disclosed
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof INTEZYNE TECHNOLOGIES, INC. 2006-06-29 US disclosed
WO-2006047419-A2 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof GNE, ALG1, EPHX2 CNR1 3636/4885CNR2 3209/4885TSHR 4037/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR CNR1 4258/4885CNR2 4234/4885TSHR 3790/4885
US-20060240092-A1 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell ABCB1, TERT, ABCB4 CNR1 4844/4885CNR2 4836/4885TSHR 2517/4885
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS LIPA, LPXN, CD47 CNR1 562/4885CNR2 583/4885TSHR 2921/4885
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery CLTB, SLC1A5, CLTA CNR1 4267/4885CNR2 3766/4885TSHR 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.